Compare Citius Pharmaceuticals Inc (CTXR) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs General Mills, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while General Mills, Inc. trades at $36.34 (market cap $19.46B). The key difference: General Mills, Inc. is far larger — about 1329.2× Citius Pharmaceuticals Inc's market cap, and General Mills, Inc. pays a 6.69% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GIS | |
|---|---|---|
Market Cap | $14.64M | $19.46B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $51.27 |
52-Week Low | $0.53 | $32.17 |
Enterprise Value | $10.86M | $32.95B |
Dividend Yield | — | 6.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
General Mills (GIS) trades at $36.60, up 1.05% with a bullish technical signal. The stock shows mixed earnings performance with recent Q2 2026 beating estimates, but faces declining revenue and negative net income margin. Analyst consensus is predominantly hold with a $36.14 price target. Cash flow trends show modest improvement, though debt levels have risen to 45% of assets. Recent news highlights cost-saving initiatives and innovation focus amid soft consumer demand.
Outlook remains cautious due to sales pressure and margin challenges, but valuation at 9.23 P/E suggests potential value. Key opportunities include $3 billion savings target by 2030 and brand investments. Risks involve persistent demand weakness, private label competition, and high debt burden. Investors should weigh cost-cutting benefits against top-line headwinds for recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
